/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}
Nathan Bryson was named chief scientific officer of Cynapsus in May 2009. Dr. Bryson previously worked as a consultant and advisor to Cynapsus since November 2007. He has contributed significantly to the drug formulation work for APL 130277 drug candidate, the development and execution of intellectual property strategy, and towards the development of clinical and regulatory plans.
Dr. Bryson draws from more than 18 years of experience in pharmaceutical development, having held scientific and executive management level positions at Flamel Technologies, Inc., Bionisis SA and Matregen Corp. Dr. Bryson has a strong knowledge of early-stage drug product development and formulation and has co-authored more than 23 patents.
He holds a BSc in chemistry from Auburn University and a PhD from the Massachusetts Institute of Technology.